Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $84.37, moving -0.62% from the previous trading session.

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

by Zacks Equity Research

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

by Zacks Equity Research

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

by Zacks Equity Research

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

Mark Vickery headshot

Top Stock Reports for Home Depot, Abbott & Bristol-Myers

by Mark Vickery

Today's Research Daily features updated research reports on 16 major stocks, including Home Depot (HD), Abbott (ABT) and Bristol-Myers (BMY).

Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.

Abbott (ABT) Down 4.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International

by Zacks Equity Research

Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International

5 Stocks Trading Near 52-Week High With More Room to Run

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

Mark Vickery headshot

Top Research Reports for Abbott, Netflix & Philip Morris

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).

Company News for Jul 18, 2019

by Zacks Equity Research

Companies In The News Are: ABT, USB, ERIC, TXT

Trina Mukherjee headshot

IVD Market Sustains Momentum: 3 Stocks in Focus

by Trina Mukherjee

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

Abbott (ABT) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance

by Zacks Equity Research

Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.

Mixed Housing Data for June

by Zacks Equity Research

Mixed Housing Data for June

Mark Vickery headshot

Housing Starts, Building Permits Mixed; Q2 for BAC, USB, ABT

by Mark Vickery

Housing Starts were up slightly for June, but Building Permits disappointed.

Abbott (ABT) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 2.50% and -0.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Sreyoshi Mukherjee headshot

US-India Trade Tensions Rise: 3 Stocks in the Line of Fire

by Sreyoshi Mukherjee

As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.